Disparities Seen in Carbapenem-Resistant Enterobacterales Bloodstream Infection Outcomes
By Lori Solomon HealthDay Reporter
TUESDAY, May 14, 2024 -- Black female patients hospitalized for carbapenem-resistant Enterobacterales (CRE) bloodstream infections (BSI) face increased 30-day mortality, according to a study presented at the annual European Society of Clinical Microbiology and Infectious Diseases Global Congress, held from April 27 to 30 in Barcelona, Spain.
Felicia Ruffin, Ph.D., from the Duke University School of Medicine in Durham, North Carolina, and colleagues investigated the relationship between the outcomes of Black and White patients with CRE BSI. The analysis included 362 patients in U.S. hospitals (April 2016 to November 2019) with BSI caused by CRE.
The researchers found that the distribution desirability of outcome ranking (no clinical response at 30 days; unsuccessful discharge or readmitted within 30 days; renal failure postculture or Clostridium difficile infection) was similar among the groups of Black and White patients. However, for 30-day mortality, the interaction between race and sex was an independent predictor. Specifically, Black women had increased 30-day mortality versus White women and Black men.
"Our findings that Black women experience higher mortality after (CRE) bloodstream infections compared with White women and Black men illustrates the importance of combining race and sex when evaluating racial and sex-related disparities in infectious disease outcomes in future studies," Ruffin said in a statement. "The distribution of comorbid conditions was different between Black and White patients and may contribute to disparities. The root causes of disparities in antimicrobial-resistance infections will require larger sample sizes and more in-depth analyses of the sources of infection in patient groups."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted May 2024
Read this next
First-Line Biparametric MRI Less Cost-Effective Than PSA for Prostate Cancer Screening
MONDAY, June 3, 2024 -- From an economic perspective, first-line prostate-specific antigen (PSA) testing is favored over biparametric magnetic resonance imaging (bpMRI) for...
9.6 Percent of Medical Visits Took Place Via Telehealth in 2021
MONDAY, June 3, 2024 -- In 2021, 9.6 percent of medical visits took place via telehealth, with a higher percentage seen for mental health visits, according to a research letter...
Digestive Disease Week, May 18-21
Digestive Disease Week, the annual meeting sponsored by the American Association for the Study of Liver Diseases, American Gastroenterological Association, American Society for...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.